Synthesis of Aryl *anti*-Vicinal Diamines via Aza-Brook Rearrangement-Initiated Nucleophilic Addition of α -Silylamines to Imines

Chao-Yang Lin,[†] Zhao Sun,[‡] Yan-Jun Xu,^{*,†} and Chong-Dao Lu^{*,†,‡}

[†]The Key Laboratory of Plant Resources and Chemistry of Arid Zones, Xinjiang Technical Institute of Physics & Chemistry, Chinese Academy of Sciences and University of the Chinese Academy of Sciences, Urumqi 830011, China

[‡]Department of Chemistry and Applied Chemistry, Changji University, Changji 831100, China

Supporting Information

ABSTRACT: An efficient protocol is described for the synthesis of vicinal diamines via aza-Brook rearrangementinitiated nucleophilic addition of α -silylamines to imines. Various symmetrical and unsymmetrical aryl diamine derivatives were prepared in moderate to high yields with high *anti/ syn* diastereoselectivity.

T he structural unit of vicinal diamines is present in a broad range of bioactive molecules as well as in ligands and organocatalysts that are useful in asymmetric catalysis.¹⁻⁸ Tremendous efforts have been made by the synthetic community to prepare this structural motif, in which the most effective synthetic protocols include diaza-Cope rearrangement,⁹ direct alkene diamination,^{7,10-12} imine-imine coupling,¹³ and aza-Henry/nitro-reduction cascades.¹⁴⁻¹⁷ Moreover, as a straightforward approach toward the synthesis of nonsymmetric 1,2-diamines, direct nucleophilic addition of an α -amino carbanion or its equivalent to imines is also notable, however, which shows *syn* selectivity in most cases.¹⁸⁻²⁴

Here we describe the *anti*-selective synthesis of symmetrical and unsymmetrical 1,2-diaryl-1,2-diamines using aryl α -silyl-amine as a precursor of the α -amino anion (Scheme 1). In this







process, a base-induced [1,2]-aza-Brook rearrangement^{25–28} of aryl α -silylamine 1 afforded the α -amino carbanion A2 that was subsequently intercepted by the imine 2 to give the *anti*diamine 3 after desilylation. The stereochemical outcome may be rationalized by considering that the coupling of A2 and 2 occurs via open transition state A3 to minimize the nonbonding interactions between the *N*-diphenylphosphinyl group of the imine and the highly hindered silylamino group of the α -amino carbanion. Notably, the described synthetic protocol represents one of the few applications of the discovery by Brook and coworkers^{29,30} in 1974 that 1,2-silyl migration of α -silylamines from carbon to nitrogen can occur in the presence of suitable bases.^{31–38}

Our preliminary investigations indicated that potassium hexamethyldisilazide (KHMDS) can efficiently trigger the envisaged [1,2]-aza-Brook rearrangement of N-phenyl α -phenyl α -silvlamines 1a to give N-phenylbenzylamine (5), whereas *n*BuLi or *t*BuLi cannot.^{39,40} Thus, further study of the reactivity of α -silvlamines and imines was conducted using KHMDS as a base. We quickly recognized that the N-protecting groups on both 1 and 2 (Scheme 1) are critical to the success of the desired transformations. The anticipated coupling reaction occurred when N-aryl α -silylamine and N-diphenylphosphinyl (N-DPP) imine were used simultaneously. For example, using 1a and 2a as coupling partners gave the desired vicinal diamine 3a in 80% yield with 10:1 dr after quenching with 1 N HCl (Scheme 2; only the major diamine diastereomer is shown in eq 1). The stereochemistry of the predominant diastereomer 3a was assigned to be anti based on X-ray crystallography.⁴¹ Carrying out the reaction at 0 or -78 °C led to similar yields and dr values. Replacing the N-DPP imine 2a with other activated imines such as N-Ts and N-Boc imines did not

Received: February 3, 2015 Published: March 10, 2015



generate any coupling products; instead, the benzylamine **5** was detected in the resulting complex mixtures.⁴² The formation of the desilylation product **5** may reflect the abstraction of a proton from the reaction mixture by the α -amino carbanion intermediate (Scheme 1, **A2**), given that other suitable electrophiles were absent. Overwhelming desilylation was also observed when KHMDS and **2a** were added stepwise to the THF solution of **1a**, which failed to give any 1,2-diamine **3a** (eq 2). Replacing the *N*-phenyl α -silylamine **1a** with *N*-Bz or *N*-tertbutylsulfinyl analogues yielded complex mixtures of unidentified products.⁴³ Attempts to improve yield and diastereose-lectivity by introducing Lewis acids⁴⁴ such as ZnBr₂ and BF₃. Et₂O proved unsuccessful; these acids completely inhibited the reaction.

Control experiments were conducted to verify the reaction mechanism. To confirm that the presumed $C \rightarrow N$ silyl migration actually occurred, we quenched the reaction with aqueous NaHCO3 rather than 1 N HCl solution and obtained the N-silyl diamine 4a (eq 1). To rule out the possibility that the coupling reaction was initiated by deprotonation at the α position of the α -silylamine, we labeled N-phenyl α -silylamine with deuterium on the α -carbon (d-1a) and coupled it to the imine 2a to afford the vicinal diamine d-3a or the N-silyl diamine d-4a with the deuterium intact (eq 3). Coupling 1a and 2a in the presence of CsF was examined,⁴⁰ and predominantly benzylamine 5 formed; the coupling product 3a was obtained in low yield (24%) with poor diastereocontrol (1.2:1 dr) showing syn selectivity (eq 4). In this case, the intermediate N-H α -amino carbanion generated from fluorideinduced desilylation did not show good stereocontrol in the coupling with N-DPP imine. This indicates that, in our

protocol, the *N*-silyl group on the α -amino carbanion (Scheme 1, A2) is important for achieving high *anti* diastereoselectivity.

Next, we examined the scope and limitations for the coupling of N-aryl α -silylamines and N-DPP imines. We were pleased to observe that the anti-selective protocol for synthesizing aryl 1,2diamines was versatile (Table 1). A range of aryl N-DPP imines coupled efficiently with α -silylamine 1a to generate the desired products in 50-90% yields with high diastereoselectivities of 8:1 to >20:1 dr (entries 1-11). Bulky tert-butyl N-DPP imine 21 was also a suitable substrate and efficiently coupled with 1a (90% yield, 14:1 dr, entry 12). Notably, enolizable N-DPP imine derived from cyclohexanecarboxaldehyde was not tolerated under these reaction conditions. The α -silylamines 1a-1 were prepared by nucleophilic addition of PhMe₂Si-MgiPr·LiCl or PhMe₂Si-Bpin (pin = pinacolato) to the corresponding aryl aldimines⁴⁵⁻⁵¹ and then used in the coupling protocol to afford aryl vicinal diamines in 58-93% yield with diastereoselectivities ranging from 6:1 to >20:1 (entries 13–23).⁵² Together, these studies suggest that a variety of symmetrical and unsymmetrical aryl anti-1,2-diamines can easily be synthesized by selecting the appropriate coupling partners.

To elucidate the potential synthetic applications of this process, the *anti*-1,2-diamine **3x** was prepared in 85% yield by combining *N*-PMP α -silylamine **1m** and *N*-DPP imine **2c** in the presence of KHMDS (Scheme 3). The coupling product **3x** was converted to the corresponding imidazolidinone **6** in order to remove the nitrogen-protecting groups.⁵³ Then **6** was treated with NaOMe to remove the DPP group and with CAN (cerium ammonium nitrate) to remove the PMP group. Finally, acidic hydrolysis (HBr/HOAc) produced the free diamine **7**.

In summary, we have developed a new method for the synthesis of aryl vicinal diamines involving the coupling of *N*-aryl α -silylamines and *N*-DPP imines. This transformation relies on base-induced [1,2]-aza-Brook rearrangement to generate *N*-silyl α -amino carbanion in situ, and it provides access to symmetrical and unsymmetrical aryl 1,2-diamines with high *anti/syn* diastereoselectivity.

EXPERIMENTAL SECTION

General Methods. All commercially available reagents were used without further purification unless otherwise stated. THF was freshly distilled from sodium benzophenone under argon atmosphere. All reactions were carried out under an argon atmosphere in flame-dried glassware under positive pressure of argon with magnetic stirring using standard Schlenk techniques. Column chromatography was performed on silica gel (200-300 mesh). Visualization on TLC (analytical thin layer chromatography) was achieved by the use of UV light (254 nm) and treatment with aqueous ceric ammonium molybdate or KMnO₄ followed by heating. ¹H NMR spectra were recorded on a 400 MHz NMR spectrometer, and ¹³C NMR spectra were recorded on a 100 MHz with solvent resonance as the internal standard (¹H NMR, $\rm CDCl_3$ at 7.26 ppm, $\rm C_6D_6$ at 7.16 ppm; $\rm ^{13}C$ NMR, $\rm CDCl_3$ at 77.1 ppm, C₆D₆ at 128.0 ppm). NMR data are reported as follows: chemical shift, multiplicity (br = broad singlet, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant (Hz), and integration. High-resolution mass spectra (HRMS) were recorded using electron spray ionization (ESI) with a time-of-flight mass analyzer.

Diphenylphosphinyl aldimines were synthesized using the procedure of Jennings and co-workers.⁵⁴ PhMe₂SiLi (approximately 1.0 M solution in THF) was prepared according to the procedure of Fleming and co-workers.⁵⁵

General Procedure for the Preparation of α -Silylamine 1. Method A. A flame-dried Schlenk tube equipped with a magnetic stirring bar was successively charged with PhMe₂SiLi (approximately Table 1. Substrate Scope for the Coupling of α -Silylamines and Imines^a

		O 1) KHN P Ph 2) 1N I Ma + N Ph	MDS PILNH HCI Ar	र	
	Ar Siphi 1	R 2	HÑ. 3 [⊳ <ph ¦ Ph)</ph 	
entry	Ar	R	product	yield ^{b} (%)	dr ^c
1	Ph (1a)	$4-MeOC_{6}H_{4}(2a)$	3a	80	10:1
2	Ph (1a)	Ph (2b)	3b	$80 \ (70)^d$	11:1
3	Ph (1a)	$4-MeC_{6}H_{4}$ (2c)	3c	87	>20:1
4	Ph (1a)	$2 - MeC_6H_4$ (2d)	3d	59	8:1
5	Ph (1a)	$3-MeOC_{6}H_{4}(2e)$	3e	83	14:1
6	Ph (1a)	$4-BrC_{6}H_{4}$ (2f)	3f	66	20:1
7	Ph (1a)	$4-FC_{6}H_{4}(2g)$	3g	90	>20:1
8	Ph (1a)	$4-ClC_{6}H_{4}$ (2h)	3h	77	14:1
9	Ph (1a)	1-naph (2i)	3i	61	9:1
10	Ph (1a)	2-furyl (2j)	3j	50	10:1
11	Ph (1a)	2-thienyl (2k)	3k	60	14:1
12	Ph (1a)	tBu (21)	31	90	14:1
13	4-MeOC ₆ H ₄ (1b)	Ph (2b)	3m	58 ^e	8:1
14	$4-FC_{6}H_{4}$ (1c)	Ph (2b)	3n	93 ^e	11:1
15	$4-BrC_{6}H_{4}$ (1d)	Ph (2b)	30	64 ^e	6:1
16	$4-ClC_{6}H_{4}$ (1e)	Ph (2b)	3p	69	10:1
17	$3-BrC_{6}H_{4}$ (1f)	Ph (2b)	3q	70	8:1
18	$4-tBuC_6H_4$ (1g)	Ph (2b)	3r	63	10:1
19	$3-\text{MeOC}_6\text{H}_4$ (1h)	Ph (2b)	3s	77 ^e	10:1
20	$3 - MeC_6H_4$ (1i)	Ph (2b)	3t	79	>20:1
21	$2 - MeC_6H_4(1j)$	Ph (2b)	3u	70	11:1
22	3,5-diMeC ₆ H ₃ (1k)	Ph (2b)	3v	90	20:1
23	3.4-diMeC ₆ H ₃ (11)	Ph (2b)	3w	90^e	10:1

^{*a*}All reactions were carried out with α -silylamine 1 (0.20 mmol), N-DPP imine 2 (0.30 mmol), KHMDS (0.50 mmol), and dry THF (2.0 mL) under argon. ^{*b*}Isolated yield of major diastereoisomers. ^{*c*}Anti/syn ratios were determined by ¹H NMR analysis of crude reaction mixtures. ^{*d*}Crude α -silylamine 1a prepared by reacting PhMe₂Si-MgiPr·LiCl with N-benzylideneaniline was used. ^{*e*}Isolated yield of an inseparable mixture of diastereoisomers.

Scheme 3. Deprotection of Nitrogen Substituents of *anti-*Vicinal Diamines



1.0 M solution in THF, 0.60 mmol, 1.5 equiv) and *i*-PrMgCl (2.0 M solution in THF, 0.60 mmol, 1.5 equiv), and the reaction mixture was maintained at 0 °C for 15 min; then the imine (0.40 mmol, 1.5 equiv) in 2.0 mL of toluene was added via syringe. The reaction was subsequently maintained at 0 °C until full conversion (TLC monitoring). The reaction was quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate (3 times). The organic extracts were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The α -silylated amine

(1a-c, 1g-n) was purified by flash column chromatography on silica gel using hexanes/dichloromethane = 5/1 as eluent.

Method B. To a flame-dried Schlenk flask were added CuCN (0.020 mmol, 5.0 mol %) and NaOMe (0.040 mmol, 10 mol %). After addition of THF (1.0 mL), the reaction mixture was maintained at room temperature for 1 h. At 0 °C, Me₂PhSiBpin (0.60 mmol, 1.5 equiv) and imine (0.40 mmol) in THF (1.0 mL) were added via syringe followed by MeOH (1.60 mmol, 4 equiv), and the reaction was subsequently maintained until full conversion (TLC monitoring). Evaporation of the solvents under reduced pressure afforded α -silylated amine (1d-f) as the crude product, which was purified by flash column chromatography using hexanes/dichloromethane = 5/1 as eluent.

N-(Phenyl)-α-(phenyldimethylsilyl)benzylamine (1a): Pale yellow oil (112 mg, 90%); $R_f = 0.60$ (hexanes/ethyl acetate = 20/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.34-7.15$ (m, 5H), 7.10-7.00 (m, 2H), 7.00-6.90 (m, 3H), 6.85 (t, J = 7.7 Hz, 2H), 6.41 (t, J = 7.3 Hz, 1H), 6.29 (d, J = 8.3 Hz, 2H), 3.99 (d, J = 5.8 Hz, 1H), 3.92 (d, J = 5.5 Hz, 1H), 0.17 (s, 3H), 0.10 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 148.6$, 142.2, 135.2, 134.5, 129.9, 129.1, 128.3, 128.2, 126.1, 125.6, 117.3, 113.6, 50.3, -4.2, -5.3; HRMS (ESI-TOF) calcd for C₂₁H₂₄NSi [M + H]⁺ m/z = 318.1673, found 318.1667.

N-(Phenyl)-α-(phenyldimethylsilyl)-4-methoxybenzylamine (1b): Yellow oil (115 mg, 83%); $R_f = 0.35$ (hexanes/ethyl acetate = 20/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.37-7.17$ (m, 5H), 6.93–6.81 (m, 4H), 6.62 (d, J = 8.7 Hz, 2H), 6.44 (t, J = 7.3 Hz, 1H), 6.33 (d, J = 7.9 Hz, 2H), 3.96 (s, 1H), 3.60 (s, 3H), 0.19 (s, 3H), 0.13 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 157.7$, 148.5, 135.3, 134.5, 133.7, 129.8, 129.0, 128.1, 127.0, 117.4, 113.8, 113.7, 55.3, 49.6, -4.3,

The Journal of Organic Chemistry

-5.2; HRMS (ESI-TOF) calcd for C₂₂H₂₆NOSi [M + H]⁺ m/z = 348.1778, found 348.1773.

N-(Phenyl)-α-(phenyldimethylsilyl)-4-fluorobenzylamine (1c): Yellow oil (80.3 mg, 60%); $R_f = 0.67$ (hexanes/ethyl acetate = 20/1); ¹H NMR (400 MHz, CDCl₃) δ = 7.50–7.40 (m, 5H), 7.11– 7.03 (m, 4H), 6.95 (t, J = 8.7 Hz, 2H), 6.66 (t, J = 7.3 Hz, 1H), 6.50 (d, J = 8.0 Hz, 2H), 4.18 (s, 1H), 0.39 (s, 3H), 0.33 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 161.2 (d, J_{C-F} = 241.5 Hz), 148.3, 137.6, 134.9, 134.4, 130.0, 129.1, 128.3, 127.4 (d, J_{C-F} = 7.7 Hz), 117.6, 115.1 (d, J_{C-F} = 24.8 Hz), 113.7, 49.8, -4.5, -5.2; HRMS (ESI-TOF) calcd for C₂₁H₂₃FNSi [M + H]⁺ m/z = 336.1578, found 336.1590.

N-(Phenyl)-α-(phenyldimethylsilyl)-4-bromobenzylamine (1d): Yellow oil (94.4 mg, 60%); $R_f = 0.62$ (hexanes/ethyl acetate = 20/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.36-7.18$ (m, 5H), 7.06 (d, J = 8.4 Hz, 2H), 6.95–6.85 (m, 4H), 6.49 (t, J = 7.3 Hz, 1H), 6.31 (d, J = 7.9 Hz, 2H), 4.00 (s, 2H), 0.22 (s, 3H), 0.15 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 148.2$, 141.5, 134.7, 134.4, 131.4, 130.1, 129.1, 128.3, 127.7, 119.1, 117.7, 113.6, 50.0, -4.5, -5.3; HRMS (ESI-TOF) calcd for C₂₁H₂₃BrNSi [M + H]⁺ m/z = 396.0778, found 396.0770.

N-(Phenyl)-*α*-(phenyldimethylsilyl)-4-chlorobenzylamine (1e): Yellow oil (111 mg, 79%); $R_f = 0.66$ (hexanes/ethyl acetate = 20/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.36-7.18$ (m, 5H), 7.06 (d, J = 8.4 Hz, 2H), 6.95–6.80 (m, 4H), 6.49 (t, J = 7.3 Hz, 1H), 6.31 (d, J = 7.9 Hz, 2H), 4.00 (s, 2H), 0.22 (s, 3H), 0.15 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 148.2$, 140.9, 134.7, 134.4, 131.1, 130.1, 129.1, 128.5, 128.2, 127.4, 117.7, 113.6, 50.0, -4.5, -5.2; HRMS (ESI-TOF) calcd for C₂₁H₂₂ClNNaSi [M + Na]⁺ m/z = 374.1102, found 374.1084.

N-(Phenyl)-*α*-(phenyldimethylsilyl)-3-bromobenzylamine (1f): Yellow oil (130 mg, 82%); $R_f = 0.58$ (hexanes/ethyl acetate = 20/ 1); ¹H NMR (400 MHz, CDCl₃) δ = 7.53–7.40 (m, 5H), 7.32–7.24 (m, 2H), 7.15–7.05 (m, 4H), 6.68 (t, *J* = 7.3 Hz, 1H), 6.51 (d, *J* = 7.8 Hz, 2H), 4.16 (s, 1H), 0.42 (s, 3H), 0.35 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 148.2, 145.1, 134.6, 134.4, 130.2, 129.9, 129.2, 129.0, 128.7, 128.3, 124.7, 122.7, 117.7, 113.6, 50.3, -4.5, -5.3; HRMS (ESI-TOF) calcd for C₂₁H₂₃BrNSi [M + H]⁺ *m*/*z* = 396.0778, found 396.0792.

N-(Phenyl)-*α*-(phenyldimethylsilyl)-4-*tert*-butylbenzylamine (1g): Yellow oil (132 mg, 88%); $R_f = 0.50$ (hexanes/ethyl acetate = 40/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.32-7.17$ (m, 5H), 7.08 (d, J = 8.4 Hz, 2H), 6.92–6.82 (m, 4H), 6.45 (t, J = 7.3 Hz, 1H), 6.35 (d, J = 7.7 Hz, 2H), 3.99 (s, 1H), 1.14 (s, 9H), 0.19 (s, 3H), 0.13 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 148.6$, 148.2, 138.7, 135.6, 134.5, 129.8, 129.1, 128.1, 125.8, 125.1, 117.4, 113.7, 49.9, 34.4, 31.6, -4.1, -5.2; HRMS (ESI-TOF) calcd for C₂₅H₃₂NSi [M + H]⁺ m/z = 374.2299, found 374.2289.

N-(Phenyl)-*α*-(phenyldimethylsilyl)-3-methoxybenzylamine (1h): Yellow oil (121 mg, 87%); $R_f = 0.52$ (hexanes/ethyl acetate = 20/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.33-7.29$ (m, 2H), 7.25–7.18 (m, 3H), 6.99 (t, J = 7.9 Hz, 1H), 6.88 (t, J = 7.8 Hz, 2H), 6.57 (d, J = 7.6 Hz, 1H), 6.51 (dd, J = 8.1, 2.5 Hz, 1H), 6.49–6.41 (m, 2H), 6.34 (d, J = 8.0 Hz, 2H), 3.99 (s, 2H), 3.51 (s, 3H), 0.21 (s, 3H), 0.14 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 159.7$, 148.7, 144.1, 135.3, 134.5, 129.9, 129.3, 129.1, 128.1, 118.6, 117.4, 113.2, 111.6, 111.1, 55.1, 50.5, -4.3, -5.2; HRMS (ESI-TOF) calcd for C₂₂H₂₆NOSi [M + H]⁺ m/z = 348.1778, found 348.1775.

N-(Phenyl)-*α*-(phenyldimethylsilyl)-3-methylbenzylamine (1i): Yellow oil (111 mg, 84%); $R_f = 0.70$ (hexanes/ethyl acetate = 40/ 1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.55-7.40$ (m, 5H), 7.19 (t, J =7.5 Hz, 1H), 7.15–7.09 (m, 2H), 6.99 (t, J = 8.0 Hz, 2H), 6.94 (s, 1H), 6.67 (t, J = 7.3 Hz, 1H), 6.56 (d, J = 7.7 Hz, 2H), 4.20 (s, 2H), 2.33 (s, 3H), 0.42 (s, 3H), 0.35 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 148.7$, 142.0, 137.7, 135.4, 134.5, 129.9, 129.1, 128.2, 128.1, 126.9, 126.4, 123.3, 117.3, 113.6, 50.3, 21.7, -4.3, -5.3; HRMS (ESI-TOF) calcd for C₂₂H₂₆NSi [M + H]⁺ m/z = 332.1829, found 332.1824.

N-(Phenyl)-α-(phenyldimethylsilyl)-2-methylbenzylamine (1j): Yellow oil (109 mg, 82%); $R_f = 0.62$ (hexanes/ethyl acetate = 40/ 1); ¹H NMR (400 MHz, CDCl₃) δ = 7.55–7.35 (m, 5H), 7.15–7.10 (m, 6H), 6.62 (t, *J* = 7.3 Hz, 1H), 6.45 (d, *J* = 8.0 Hz, 2H), 4.43 (s, 1H), 4.20 (br, 1H), 2.30 (s, 3H), 0.39 (s, 3H), 0.35 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 148.5, 140.2, 135.5, 134.6, 134.1, 130.4, 129.9, 129.0, 128.1, 126.3, 125.9, 125.4, 117.4, 113.3, 45.7, 20.0, -4.1, -5.2; HRMS (ESI-TOF) calcd for C₂₂H₂₆NSi $[M + H]^+$ m/z = 332.1829, found 332.1815.

N-(Phenyl)-α-(phenyldimethylsilyl)-3,5-dimethylbenzylamine (1k): Yellow oil (123 mg, 87%); $R_f = 0.55$ (hexanes/ethyl acetate = 40/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.54-7.38$ (m, 5H), 7.13–7.06 (m, 2H), 6.81 (s, 1H), 6.74 (s, 2H), 6.66 (t, J = 7.3 Hz, 1H), 6.56 (d, J = 7.7 Hz, 2H), 4.13 (s, 1H), 2.28 (s, 6H), 0.39 (s, 3H), 0.33 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 148.9$, 141.9, 137.5, 135.5, 134.5, 129.8, 129.0, 128.0, 127.3, 124.1, 117.3, 113.6, 50.3, 21.5, -4.3, -5.3; HRMS (ESI-TOF) calcd for C₂₃H₂₈NSi [M + H]⁺ m/z = 346.1986, found 346.1982.

N-(Phenyl)-α-(phenyldimethylsilyl)-4,5-dimethylbenzylamine (1l): Yellow oil (117 mg, 82%); $R_f = 0.60$ (hexanes/ethyl acetate = 40/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.57-7.37$ (m, 5H), 7.12–7.00 (m, 3H), 6.88 (d, J = 6.8 Hz, 2H), 6.64 (t, J = 7.3 Hz, 1H), 6.54 (d, J = 7.9 Hz, 2H), 4.14 (s, 1H), 2.25 (s, 3H), 2.21 (s, 3H), 0.38 (s, 3H), 0.32 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 148.7$, 139.2, 136.1, 135.6, 134.5, 133.6, 129.8, 129.6, 129.1, 128.0, 127.6, 123.6, 117.3, 113.7, 50.0, 20.0, 19.5, -4.2, -5.2; HRMS (ESI-TOF) calcd for C₂₃H₂₇NNaSi [M + Na]⁺ m/z = 368.1805, found 368.1801.

N-(4-Methoxyphenyl)-*α*-(phenyldimethylsilyl)-benzylamine (1m): Yellow oil (98.7 mg, 79%); $R_f = 0.45$ (hexanes/ethyl acetate = 20/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.65-7.48$ (m, 5H), 7.40–7.34 (m, 2H), 7.30–7.20 (m, 3H), 6.78 (d, J = 8.9 Hz, 2H), 6.58 (d, J = 8.6 Hz, 2H), 4.26 (s, 1H), 3.80 (s, 3H), 0.49 (s, 3H), 0.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 152.1$, 142.2, 135.4, 134.5, 133.2, 129.9, 128.3, 128.1, 126.3, 125.6, 122.3, 114.8, 55.8, 51.3, -4.2, -5.3; HRMS (ESI-TOF) calcd for C₂₂H₂₆NOSi [M + H]⁺ m/z = 348.1778, found 348.1773.

N-(Phenyl)-*α*-(phenyldimethylsilyl)-*α*-*b*-benzylamine (d-1a): Yellow oil (114 mg, 89%); $R_f = 0.55$ (hexanes/ethyl acetate = 40/ 1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.30-7.14$ (m, 5H), 7.02 (t, J = 7.4 Hz, 2H), 6.95–6.85 (m, 3H), 6.83 (t, J = 7.9 Hz, 2H), 6.40 (t, J = 7.3 Hz, 1H), 6.28 (d, J = 8.2 Hz, 2H), 4.04 (br, 1H), 0.15 (s, 3H), 0.08 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 148.5$, 142.1, 135.2, 134.4, 129.9, 129.1, 128.3, 128.1, 126.1, 125.6, 117.4, 113.6, 49.8 (t, $J_{C-D} = 31.4$ Hz), -4.3, -5.2; HRMS (ESI-TOF) calcd for C₂₁H₂₂DNNaSi [M + Na]⁺ m/z = 341.1555, found 341.1562.

N-(2-(N-(Phenyl)-N-(phenyldimethylsilyl))-1-(4-methoxyphenyl)-2-phenylethyl)-P,P-diphenylphosphinic Amide (4a). 1a (0.20 mmol, 63.5 mg) and 2a (0.30 mmol, 101 mg, 1.5 equiv) were dissolved in 2.0 mL of THF in a flame-dried Schlenk flask under argon. At 0 °C, KHMDS (0.5 M solution in toluene, 0.50 mmol) was added dropwise to the solution via syringe, and the reaction mixture was stirred for 1 h; then it was quenched by the addition of 1.0 mL of saturated aqueous sodium bicarbonate. The reaction mixture was extracted with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by flash column chromatography using (hexanes/ethyl acetate/triethylamine = 100/ 50/1) as eluent to give 4a (108 mg, 83%) as a pale yellow solid: mp 55-57 °C; $R_f = 0.25$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, C_6D_6) $\delta = 7.43 - 7.37$ (m, 3H), 7.37 - 7.32 (m, 3H), 7.32 - 7.25 (m, 2H), 7.23 7.16 (m, 8H), 6.99-6.79 (m, 9H), 6.72 (dd, J = 12.6, 7.5 Hz, 4H), 5.18-5.06 (m, 1H), 4.92 (d, J = 10.7 Hz, 1H), 3.41 (s, 3H), 2.98 (t, J = 8.0 Hz, 1H), 0.11 (s, 3H), 0.09 (s, 3H); ¹³C NMR $(100 \text{ MHz}, C_6D_6) \delta = 159.4, 143.4, 141.5, 138.9, 135.8, 135.3, 134.9,$ 134.7, 134.5, 133.8, 133.4, 132.8 (d, J_{C-P} = 9.6 Hz), 131.8 (d, J_{C-P} = 9.9 Hz), 131.1, 131.0 (d, J_{C-P} = 9.9 Hz), 130.7, 130.6, 129.4, 128.2, 127.7, 127.3, 125.7, 113.8, 68.5, 55.4, 55.0, 0.0, -0.6; HRMS (ESI-TOF) calcd for $C_{41}H_{42}N_2O_2PSi [M + H]^+ m/z = 653.2748$, found 653.2732

N-(2-(*N*-(Phenyl)-*N*-(phenyldimethylsilyl))-1-(4-methoxyphenyl)-2-D-2-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (d-4a): Pale yellow solid; mp 58–59 °C; $R_f = 0.25$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, C_6D_6) $\delta = 7.44-7.32$ (m, 6H), 7.22– 7.24 (m, 2H), 7.24–7.16 (m, 8H), 6.99–6.90 (m, 5H), 6.90–6.79 (m, 4H), 6.76–6.67 (m, 4H), 5.11 (t, J = 8.0 Hz, 1H), 3.41 (s, 3H), 2.98 (t, J = 8.0 Hz, 1H), 0.11 (s, 3H), 0.09 (s, 3H); ¹³C NMR (100 MHz, $\begin{array}{l} C_6 D_6 \ \delta = 159.4, 143.4, 141.4, 138.9, 135.7, 135.2, 134.9, 134.6, 134.5, \\ 133.8, 133.4, 132.8 \ (d, J_{C-P} = 9.7 \ Hz), 131.8 \ (d, J_{C-P} = 9.9 \ Hz), 131.1, \\ 131.0 \ (d, J_{C-P} = 12.3 \ Hz), 130.7, 130.6, 129.4, 128.2, 127.7, 127.3, \\ 125.7, 113.8, 68.0, 55.3, 55.0, 0.0, -0.6; HRMS \ (ESI-TOF) \ calcd \ for \\ C_{41}H_{41}DN_2O_2PSi \ [M + H]^+ \ m/z = 654.2810, \ found \ 654.2812. \end{array}$

General Procedure for the Preparation of 3. 1 (0.20 mmol) and 2 (0.30 mmol, 1.5 equiv) were dissolved in 2.0 mL of THF in a flame-dried Schlenk flask under argon. Then KHMDS (0.50 mmol) was added dropwise via syringe at 0 °C; the reaction mixture was stirred for 1 h and quenched by the addition of 2.0 mL of 1.0 M solution of HCl, and the resulting heterogeneous mixture was allowed to warm to room temperature and stirred for an additional 0.5 h. The reaction mixture was extracted with EtOAc (3×15 mL), and the combined organic layers were washed with aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by column chromatography.

anti-N-(2-(N-(Phenyl)-1-(4-methoxyphenyl)-2-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (*anti*-3a): White solid (83.3 mg, 80%); mp 242–243 °C; *R*_f = 0.55 (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃) δ = 7.95–7.85 (m, 2H), 7.83–7.73 (m, 2H), 7.57–7.41 (m, 4H), 7.35–7.28 (m, 2H), 7.20–7.10 (m, 3H), 7.05 (t, *J* = 7.9 Hz, 2H), 6.95–6.80 (m, 6H), 6.65 (d, *J* = 7.6 Hz, 1H), 6.63–6.54 (m, 3H), 4.84–4.68 (m, 2H), 3.84 (s, 3H), 3.33 (dd, *J* = 12.0, 7.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ = 158.9, 147.0, 137.4, 133.4, 132.8 (d, *J*_{C-P} = 9.8 Hz), 132.40 (d, *J*_{C-P} = 7.8 Hz), 132.3 (d, *J*_{C-P} = 2.7 Hz), 132.2 (d, *J*_{C-P} = 2.7 Hz), 132.1, 131.62 (d, *J*_{C-P} = 9.7 Hz), 131.55, 130.2, 129.1, 128.9, 128.7 (d, *J*_{C-P} = 9.7 Hz), 128.6, 128.4, 128.1 (d, *J*_{C-P} = 9.7 Hz), 127.5, 116.8, 113.6, 113.5, 63.1, 59.1, 55.4; HRMS (ESI-TOF) calcd for C₃₃H₃₁N₂NaO₂P [M + Na]⁺ m/z = 541.2015, found 541.2024.

syn-N-(2-(*N*-(Phenyl)-1-(4-methoxyphenyl)-2-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (*syn*-3a): White solid (7.6 mg, 7%); mp 203–205 °C; $R_f = 0.56$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.83-7.66$ (m, 4H), 7.50–7.35 (m, 4H), 7.35–7.28 (m, 2H), 7.15–7.00 (m, 7H), 6.75–6.67 (m, 4H), 6.67–6.57 (m, 3H), 6.40 (d, *J* = 3.4 Hz, 1H), 4.40 (dd, *J* = 9.2, 4.0 Hz, 1H), 4.29–4.17 (m, 1H), 3.78 (s, 3H), 3.58 (dd, *J* = 10.6, 7.9 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 158.9$, 148.0, 140.9, 133.3, 133.1 (d, $J_{C-P} = 9.9$ Hz), 132.8 (d, $J_{C-P} = 5.9$ Hz), 132.2 (d, $J_{C-P} = 7.7$ Hz), 132.0, 131.8, 131.5 (d, $J_{C-P} = 9.8$ Hz), 130.4, 129.1, 128.8, 128.6 (d, $J_{C-P} = 7.0$ Hz), 128.5, 128.0 (d, $J_{C-P} = 17.7$ Hz), 127.1, 116.9, 113.6, 113.4, 65.5, 60.9, 55.3; HRMS (ESI-TOF) calcd for C₃₃H₃₁N₂NaO₂P [M + Na]⁺ m/z = 541.2015, found 541.2017.

N-(2-(*N*-(Phenyl)-1-(4-methoxyphenyl)-2-D-2-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (d-3a): White solid (99.4 mg, 86%); mp 240–241 °C; $R_f = 0.45$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.92-7.83$ (m, 2H), 7.78 (dd, *J* = 12.0, 7.2 Hz, 2H), 7.55–7.40 (m, 4H), 7.37–7.32 (m, 2H), 7.20–7.10 (m, 3H), 7.06 (t, *J* = 7.8 Hz, 2H), 6.93–6.80 (m, 6H), 6.68–6.55 (m, 3H), 4.81 (t, *J* = 11.8 Hz, 1H), 3.84 (s, 3H), 3.33 (dd, *J* = 12.2, 6.9 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 158.9$, 146.6, 137.1, 133.3, 132.8 (d, *J*_{C-P} = 9.7 Hz), 132.3 (d, *J*_{C-P} = 2.5 Hz), 132.2 (d, *J*_{C-P} = 2.8 Hz), 132.0, 131.6 (d, *J*_{C-P} = 9.7 Hz), 131.5, 130.1, 129.1, 128.9, 128.8 (d, *J*_{C-P} = 4.3 Hz), 128.6, 128.5, 128.1 (d, *J*_{C-P} = 11.5 Hz), 127.5, 117.2, 113.9, 113.7, 62.9 (t, *J*_{C-D} = 19.9 Hz), 59.0, 55.3; HRMS (ESI-TOF) calcd for C₃₃H₃₁DN₂O₂P [M + H]⁺ m/z = 520.2259, found 520.2244.

N-(2-(*N*-(Phenyl)-1,2-diphenylethyl)-*P*,*P*-diphenylphosphinic Amide (3b): White solid (78.2 mg, 80%); mp 175–177 °C; $R_f = 0.62$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃) $\delta =$ 7.93–7.84 (m, 2H), 7.77 (dd, J = 12.1, 8.0 Hz, 2H), 7.56–7.50 (m, 1H), 7.50–7.40 (m, 3H), 7.35–7.27 (m, 5H), 7.20–7.03 (m, 6H), 7.00–6.93 (m, 2H), 6.88 (d, J = 7.3 Hz, 2H), 6.67–6.57 (m, 3H), 4.90–4.75 (m, 2H), 3.41 (dd, J = 11.9, 6.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) $\delta =$ 146.7, 140.2 (d, $J_{C-P} =$ 7.6 Hz), 136.9, 133.2, 132.8 (d, $J_{C-P} =$ 9.7 Hz), 132.4 (d, $J_{C-P} =$ 2.4 Hz), 132.3 (d, $J_{C-P} =$ 2.4 Hz), 131.9, 131.6 (d, $J_{C-P} =$ 9.7 Hz), 131.3, 130.0, 129.1, 128.9, 128.8 (d, $J_{C-P} =$ 6.3 Hz), 128.6, 128.3 (d, $J_{C-P} =$ 5.0 Hz), 128.1, 127.6, 126.9, 117.1, 113.6, 63.2, 59.6; HRMS (ESI-TOF) calcd for C₃₂H₃₀N₂OP [M + H]⁺ m/z = 489.2090, found 489.2070. *N*-(2-(*N*-(Phenyl)-1-(4-methylphenyl)-2-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3c): White solid (91.3 mg, 87%); mp 151−153 °C; $R_f = 0.65$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, C_6D_6) $\delta = 8.07-7.96$ (m, 4H), 7.91 (d, J = 7.6 Hz, 1H), 7.15–7.09 (m, 2H), 7.05–6.97 (m, 7H), 6.94–6.87 (m, 4H), 6.85–6.78 (m, 3H), 6.67 (t, J = 7.3 Hz, 1H), 6.57 (d, J = 8.0 Hz, 2H), 4.95 (td, J = 12.3, 2.2 Hz, 1H), 4.79 (dd, J = 7.6, 2.5 Hz, 1H), 3.39 (dd, J = 12.4, 6.5 Hz, 1H), 2.08 (s, 3H); ¹³C NMR (100 MHz, C_6D_6) $\delta = 148.0$, 138.3 (d, $J_{C-P} = 8.3$ Hz), 137.9, 136.8, 134.4, 133.2 (d, $J_{C-P} = 9.6$ Hz), 132.7, 132.08, 132.09 (d, $J_{C-P} = 4.3$ Hz), 132.07, 131.8 (d, $J_{C-P} = 9.5$ Hz), 131.4, 129.6, 129.1, 129.0, 128.9, 128.7, 127.7, 127.1, 117.1, 113.8, 63.5, 59.7, 21.0; HRMS (ESI-TOF) calcd for $C_{33}H_{31}N_2NaOP$ [M + Na]⁺ m/z = 525.2066, found 525.2045.

N-(2-(*N*-(Phenyl)-1-(2-methylphenyl)-2-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3d): White solid (61.9 mg, 59%); mp 90–91 °C; $R_f = 0.63$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, C_6D_6) δ = 8.03–7.95 (m, 2H), 7.94–7.87 (m, 2H), 7.81 (d, *J* = 7.8 Hz, 1H), 7.13–7.03 (m, 3H), 7.03–6.91 (m, 10H), 6.91–6.82 (m, 5H), 6.67–6.61 (m, 1H), 6.47 (d, *J* = 7.7 Hz, 1H), 5.15 (td, *J* = 12.2, 2.2 Hz, 1H), 4.71 (dd, *J* = 7.9, 2.2 Hz, 1H), 3.52 (dd, *J* = 12.3, 6.7 Hz, 1H), 1.78 (s, 3H); ¹³C NMR (100 MHz, C_6D_6) δ = 147.8, 139.4 (d, *J*_{C-P} = 7.6 Hz), 137.7, 135.0, 134.1, 133.1 (d, *J*_{C-P} = 9.5 Hz), 132.9, 132.7, 132.2, 132.0, 131.9 (d, *J*_{C-P} = 9.5 Hz), 131.4, 130.7, 129.5, 129.3, 129.0, 128.8 (d, *J*_{C-P} = 5.2 Hz), 128.6 (d, *J*_{C-P} = 7.9 Hz), 127.5, 127.0, 125.7, 117.2, 113.9, 61.4, 56.8, 18.8; HRMS (ESI-TOF) calcd for $C_{33}H_{32}N_2OP$ [M + H]⁺ *m*/*z* = 503.2252, found 503.2261.

N-(2-(*N*-(Phenyl)-1-(3-methoxyphenyl)-2-phenylethyl)-*P*,*P*diphenylphosphinic Amide (3e): White solid (86.1 mg, 83%); mp 172–173 °C; $R_f = 0.50$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, C_6D_6) δ = 8.06–7.96 (m, 4H), 7.84 (d, *J* = 7.5 Hz, 1H), 7.12 (t, *J* = 7.8 Hz, 2H), 7.04–6.88 (m, 11H), 6.85–6.76 (m, 3H), 6.70–6.60 (m, 2H), 6.48 (s, 1H), 6.32 (d, *J* = 7.6 Hz, 1H), 4.98 (td, *J* = 12.1, 2.2 Hz, 1H), 4.84 (dd, *J* = 7.5, 2.4 Hz, 1H), 3.44 (dd, *J* = 12.4, 6.2 Hz, 1H), 3.22 (s, 3H); ¹³C NMR (100 MHz, C_6D_6) δ = 160.1, 147.9, 142.9 (d, *J*_{C-P} = 8.3 Hz), 137.9, 134.2, 133.2 (d, *J*_{C-P} = 9.6 Hz), 133.0, 132.7, 132.1 (d, *J*_{C-P} = 2.6 Hz), 131.8 (d, *J*_{C-P} = 9.6 Hz), 131.3, 129.6, 129.4, 129.0, 128.9 (d, *J*_{C-P} = 2.3 Hz), 128.8, 127.7, 119.5, 117.2, 113.9, 113.3, 112.9, 63.5, 59.9, 54.8; HRMS (ESI-TOF) calcd for $C_{33}H_{31}N_2NaO_2P$ [M + Na]⁺ m/z = 541.2015, found 541.2018.

N-(2-(*N*-(Phenyl)-1-(4-bromophenyl)-2-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3f): White solid (75.0 mg, 66%); mp 205–206 °C; *R*_f = 0.55 (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃) δ = 7.93–7.83 (m, 2H), 7.75 (dd, *J* = 12.2, 7.3 Hz, 2H), 7.59–7.51 (m, 1H), 7.51–7.40 (m, 6H), 7.37–7.30 (m, 2H), 7.20–7.11 (m, 3H), 7.06 (t, *J* = 7.8 Hz, 2H), 6.89 (d, *J* = 6.2 Hz, 2H), 6.84 (d, *J* = 8.3 Hz, 2H), 6.61 (t, *J* = 8.0 Hz, 3H), 4.88–4.61 (m, 2H), 3.36 (dd, *J* = 12.1, 6.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ = 146.4, 139.3 (d, *J*_{C−P} = 7.9 Hz), 136.6, 132.9, 132.7 (d, *J*_{C−P} = 9.8 Hz), 132.5 (d, *J*_{C−P} = 2.5 Hz), 132.4 (d, *J*_{C−P} = 2.5 Hz), 131.6, 131.5 (d, *J*_{C−P} = 1.9 Hz), 128.7, 128.3 (d, *J*_{C−P} = 2.0 Hz), 127.8, 121.5, 117.3, 113.9, 63.1, 59.1; HRMS (ESI-TOF) calcd for C₃₂H₂₈BrN₂NaOP [M + Na]⁺ m/z = 589.1015, found 589.1018.

N-(2-(*N*-(Phenyl)-1-(4-fluorophenyl)-2-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3g): White solid (87.5 mg, 90%); mp 181–182 °C; $R_f = 0.56$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.95-7.84$ (m, 2H), 7.81–7.73 (m, 2H), 7.57–7.50 (m, 1H), 7.50–7.41 (m, 3H), 7.37–7.29 (m, 2H), 7.20–7.11 (m, 3H), 7.06 (t, *J* = 7.9 Hz, 2H), 7.00 (t, *J* = 8.6 Hz, 2H), 6.96–6.87 (m, 4H), 6.69–6.58 (m, 3H), 4.85 (t, *J* = 11.7 Hz, 1H), 4.75 (d, *J* = 2.0 Hz, 1H), 3.38 (dd, *J* = 12.0, 6.5 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 162.1$ (d, $J_{C-F} = 244.7$ Hz), 146.5, 136.8, 136.1 (d, $J_{C-P} = 7.6$ Hz), 133.0, 132.7 (d, $J_{C-P} = 9.7$ Hz), 132.44 (d, $J_{C-P} = 2.5$ Hz), 132.35 (d, $J_{C-P} = 2.6$ Hz), 131.8, 131.6 (d, $J_{C-F} = 4.2$ Hz), 128.5, 128.3 (d, $J_{C-P} = 4.8$ Hz), 127.7, 117.3, 115.2 (d, $J_{C-F} = 21.2$ Hz), 113.8, 63.2, 58.9; HRMS (ESI-TOF) calcd for C₃₂H₂₈FN₂NaOP [M + Na]⁺ m/z = 529.1815, found 529.1818.

N-(2-(N-(Phenyl)-1-(4-Chlorophenyl)-2-phenylethyl)-P,P-diphenylphosphinic Amide (3h): White solid (80.1 mg, 77%); mp 215–217 °C; $R_f = 0.63$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃) δ = 7.89–7.80 (m, 2H), 7.79–7.69 (m, 2H), 7.54–7.48 (m, 1H), 7.47–7.39 (m, 3H), 7.34–7.27 (m, 2H), 7.23 (d, *J* = 4.2 Hz, 2H), 7.16–7.08 (m, 3H), 7.07–7.00 (m, 2H), 6.92–6.82 (m, 4H), 6.65–6.54 (m, 3H), 4.82 (t, *J* = 11.8 Hz, 1H), 4.73 (d, *J* = 2.2 Hz, 1H), 3.33 (dd, *J* = 12.1, 6.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ = 146.2, 138.8 (d, J_{C-P} = 7.8 Hz), 136.5, 133.4, 132.9, 132.7 (d, J_{C-P} = 9.8 Hz), 132.5 (d, J_{C-P} = 2.7 Hz), 132.4 (d, J_{C-P} = 2.8 Hz), 131.7, 131.6 (d, J_{C-P} = 9.8 Hz), 131.1, 130.4, 129.8, 129.1, 129.0, 128.8 (d, J_{C-P} = 2.8 Hz), 138.7, 128.5, 128.3 (d, J_{C-P} = 2.2 Hz), 127.8, 117.6, 114.0, 63.3, 59.0; HRMS (ESI-TOF) calcd for C₃₂H₂₈ClN₂NaOP [M + Na]⁺ m/z = 545.1520, found 545.1520.

N-(2-(*N*-(Phenyl)-1-(naphthalen-1-yl)-2-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3i): White solid (66.3 mg, 61%); mp 180–182 °C; $R_f = 0.64$ (hexanes/ethyl acetate = 2/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.99-7.83$ (m, 5H), 7.78 (dd, *J* = 12.2, 7.6 Hz, 2H), 7.58–7.43 (m, 5H), 7.44–7.31 (m, 2H), 7.25–7.17 (m, 2H), 7.13 (t, *J* = 7.2 Hz, 1H), 7.10–7.00 (m, 4H), 6.89 (d, *J* = 7.2 Hz, 1H), 6.68 (d, *J* = 7.3 Hz, 2H), 6.65–6.55 (m, 3H), 5.60 (t, *J* = 11.9 Hz, 1H), 4.93 (d, *J* = 6.6 Hz, 1H), 3.39 (dd, *J* = 12.1, 6.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 147.0$, 137.1, 136.1 (d, $J_{C-P} = 9.7$ Hz), 133.8, 133.3, 132.6 (d, $J_{C-P} = 9.8$ Hz), 132.4 (d, $J_{C-P} = 2.7$ Hz), 132.0 (129.2, 129.0, 128.6 (d, $J_{C-P} = 2.0$ Hz), 128.6 (d, $J_{C-P} = 2.4$ Hz), 128.4, 127.9, 127.6, 126.9, 126.0, 124.8, 124.3, 122.6, 116.6, 113.5, 61.2, 56.2; HRMS (ESI-TOF) calcd for C₃₆H₃₁N₂NaOP [M + Na]⁺ m/z = 561.2066, found 561.2075.

N-(2-(*N*-(Phenyl)-1-(furan-2-yl)-2-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3j): White solid (47.5 mg, 50%); mp 91–93 °C; $R_f = 0.50$ (hexanes/ethyl acetate = 2/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 8.00-7.80$ (m, 4H), 7.59–7.34 (m, 7H), 7.21–7.13 (m, 3H), 7.08 (t, *J* = 7.8 Hz, 2H), 7.04–6.96 (m, 2H), 6.67 (d, *J* = 7.9 Hz, 3H), 6.61 (t, *J* = 7.2 Hz, 1H), 6.34 (s, 1H), 6.07 (d, *J* = 3.0 Hz, 1H), 5.07 (s, 1H), 4.84–4.72 (m, 1H), 3.23 (dd, *J* = 12.0, 7.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 153.5$ (d, *J*_{C-P} = 1.0 Hz), 147.0, 142.0, 137.7, 133.0, 132.7 (d, *J*_{C-P} = 9.7 Hz), 132.41 (d, *J*_{C-P} = 2.7 Hz), 132.36 (d, *J*_{C-P} = 2.8 Hz), 131.7, 131.6 (d, *J*_{C-P} = 9.7 Hz), 131.3, 129.9, 129.1, 128.9 (d, *J*_{C-P} = 6.4 Hz), 128.7 (d, *J*_{C-P} = 6.5 Hz), 128.3, 127.8, 127.5, 117.0, 113.7, 110.7, 107.7, 60.4, 55.4; HRMS (ESI-TOF) calcd for C₃₀H₂₇N₂NaO₂P [M + Na]⁺ m/z = 501.1702, found 501.1711.

N-(2-(*N*-(Phenyl)-1-(thiophen-2-yl)-2-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3k): White solid (59.1 mg, 60%); mp 158–160 °C; $R_f = 0.55$ (hexanes/ethyl acetate = 2/1); ¹H NMR (400 MHz, CDCl₃) $\delta = 8.01-7.89$ (m, 4H), 7.61–7.43 (m, 4H), 7.43–7.32 (m, 2H), 7.24 (d, *J* = 5.0 Hz, 1H), 7.20–7.12 (m, 3H), 7.12–7.05 (m, 4H), 7.04–6.98 (m, 1H), 6.79 (d, *J* = 3.1 Hz, 1H), 6.70 (d, *J* = 7.9 Hz, 2H), 6.63 (t, *J* = 7.3 Hz, 1H), 5.10–4.90 (m, 2H), 3.42 (dd, *J* = 12.0, 6.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 146.4$, 145.3 (d, *J*_{C-P} = 9.8 Hz), 137.0, 132.8, 132.7 (d, *J*_{C-P} = 9.9 Hz), 132.5 (d, *J*_{C-P} = 2.6 Hz), 132.4 (d, *J*_{C-P} = 1.7 Hz), 131.7 (d, *J*_{C-P} = 9.7 Hz), 131.6, 131.1, 129.8, 129.1, 128.9, 128.8, 128.7, 128.3 (d, *J*_{C-P} = 10.1 Hz), 127.7, 127.3, 124.4 (d, *J*_{C-P} = 14.2 Hz), 117.5, 114.0, 63.3, 56.7; HRMS (ESI-TOF) calcd for C₃₀H₂₇N₂NaOPS [M + Na]⁺ m/z = 517.1474, found 517.1473.

N-(2-(*N*-(Phenyl)-1-*tert*-butyl-2-phenylethyl)-*P*,*P*-diphenyl-phosphinic Amide (3l): White solid (83.8 mg, 90%); mp 130–131 °C; $R_f = 0.56$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, C_6D_6) $\delta = 8.17-8.09$ (m, 2H), 8.09–8.00 (m, 3H), 7.59 (d, *J* = 7.2 Hz, 2H), 7.14 (s, 1H), 7.12–7.05 (m, 5H), 7.04–6.99 (m, 3H), 6.91 (t, *J* = 7.3 Hz, 2H), 6.84 (t, *J* = 7.3 Hz, 1H), 6.66 (t, *J* = 7.1 Hz, 1H), 6.60 (t, *J* = 7.2 Hz, 1H), 4.92 (dd, *J* = 10.0, 1.2 Hz, 1H), 3.44–3.35 (m, 1H), 3.11 (dd, *J* = 12.4, 5.3 Hz, 1H), 0.66 (s, 9H); ¹³C NMR (100 MHz, C_6D_6) $\delta = 148.1$, 140.9, 134.0, 133.3 (d, *J*_{C-P} = 9.5 Hz), 132.7, 132.5, 132.4 (d, *J*_{C-P} = 8.8 Hz), 132.3 (d, *J*_{C-P} = 12.1 Hz), 128.4, 127.5, 117.1, 114.1, 65.3, 56.6, 35.7, 27.8; HRMS (ESI-TOF) calcd for $C_{30}H_{34}N_2OP$ [M + H]⁺ *m/z* = 469.2403, found 469.2400.

N-(2-(*N*-(Phenyl)-2-(4-methoxyphenyl)-1-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3m): White solid (61.1 mg, 58%); mp 160–161 °C; $R_f = 0.58$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400

MHz, CDCl₃, major isomer) δ = 7.90 (dd, *J* = 12.0, 7.1 Hz, 2H), 7.78 (dd, *J* = 12.1, 7.6 Hz, 2H), 7.56–7.50 (m, 1H), 7.50–7.40 (m, 3H), 7.35–7.27 (m, 5H), 7.06 (t, *J* = 7.8 Hz, 2H), 7.02–6.96 (m, 2H), 6.79 (d, *J* = 8.5 Hz, 2H), 6.68–6.56 (m, 5H), 4.97–4.78 (m, 1H), 4.74 (d, *J* = 4.3 Hz, 1H), 3.70 (s, 3H), 3.37 (dd, *J* = 12.1, 6.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃, major isomer) δ = 158.9, 147.0, 140.4 (d, *J*_{C-P} = 3.9 Hz), 133.3, 132.7 (d, *J*_{C-P} = 9.8 Hz), 132.3 (d, *J*_{C-P} = 2.5 Hz), 132.2 (d, *J*_{C-P} = 2.8 Hz), 132.0, 131.6 (d, *J*_{C-P} = 9.5 Hz), 131.5, 130.1, 129.4, 129.0, 128.9, 128.7 (d, *J*_{C-P} = 8.1 Hz), 128.6, 128.3, 127.5, 126.9, 116.8, 113.5, 62.4, 59.7, 50.9; HRMS (ESI-TOF) calcd for C₃₃H₃₁N₂NaO₂P [M + Na]⁺ m/z = 541.2015, found 541.2022.

N-(2-(*N*-(Phenyl)-2-(4-fluorophenyl)-1-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3n): White solid (94.0 mg, 93%); mp 150−151 °C; $R_f = 0.55$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃, major isomer) $\delta = 7.94-7.85$ (m, 2H), 7.78 (dd, *J* = 12.2, 7.3 Hz, 2H), 7.58−7.51 (m, 1H), 7.51−7.41 (m, 3H), 7.36−7.28 (m, 5H), 7.07 (t, *J* = 7.8 Hz, 2H), 7.02−6.94 (m, 2H), 6.86−6.75 (m, 5H), 6.65−6.55 (m, 3H), 4.89−4.72 (m, 2H), 3.29 (dd, *J* = 12.2, 7.1 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃, major isomer) $\delta = 162.3$ (d, *J*_{C−F} = 244.4 Hz), 146.7, 140.0 (d, *J*_{C−P} = 8.1 Hz), 133.2, 132.9 (d, *J*_{C−F} = 3.0 Hz), 132.7 (d, *J*_{C−P} = 9.9 Hz), 132.4 (d, *J*_{C−P} = 2.7 Hz), 132.3 (d, *J*_{C−F} = 7.9 Hz), 129.1, 129.0, 128.8 (d, *J*_{C−P} = 8.8 Hz), 128.6, 128.4, 127.7, 126.9, 117.0, 115.1 (d, *J*_{C−F} = 21.1 Hz), 113.5, 62.5, 59.6; HRMS (ESI-TOF) calcd for C₃₂H₂₉FN₂OP [M + H]⁺ m/z = 507.1996, found 507.1995.

N-(2-(*N*-(Phenyl)-2-(4-bromophenyl)-1-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (30): White solid (68.8 mg, 64%); mp 190–193 °C; $R_f = 0.55$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃, major isomer) $\delta = 7.87$ (dd, J = 11.6, 7.5 Hz, 2H), 7.76 (dd, J = 11.8, 7.7 Hz, 2H), 7.56–7.49 (m, 1H), 7.49–7.39 (m, 3H), 7.35–7.26 (m, 5H), 7.26–7.19 (m, 3H), 7.05 (t, J = 7.6 Hz, 2H), 6.97 (s, 2H), 6.80 (s, 1H), 6.73 (d, J = 8.2 Hz, 2H), 6.66–6.52 (m, 3H), 4.83 (t, J = 11.7 Hz, 1H), 4.72 (d, J = 2.8 Hz, 1H), 3.30–3.12 (m, 1H); ¹³C NMR (100 MHz, CDCl₃, major isomer) $\delta = 146.6, 139.9$ (d, $J_{C-P} = 7.7$ Hz), 136.4, 133.1, 132.7 (d, $J_{C-P} = 9.8$ Hz), 132.5 (d, $J_{C-P} = 2.5$ Hz), 132.3 (d, $J_{C-P} = 2.7$ Hz), 131.8, 131.5 (d, $J_{C-P} = 9.7$ Hz), 131.4, 131.2, 130.1, 129.1, 129.0, 128.8 (d, $J_{C-P} = 9.4$ Hz), 128.6, 128.5, 127.7, 126.8, 121.5, 117.0, 113.4, 62.6, 59.4; HRMS (ESI-TOF) calcd for C₃₂H₂₉BrN₂OP [M + H]⁺ m/z = 567.1195, found 567.1202.

N-(2-(*N*-(Phenyl)-2-(4-chlorophenyl)-1-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3p): White solid (72.5 mg, 69%); mp 113–114 °C; $R_f = 0.60$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃) δ = 7.89 (dd, *J* = 12.0, 7.1 Hz, 2H), 7.77 (dd, *J* = 12.2, 7.3 Hz, 2H), 7.57–7.41 (m, 4H), 7.38–7.28 (m, 5H), 7.13–7.03 (m, 4H), 7.02–6.94 (m, 2H), 6.80 (d, *J* = 8.3 Hz, 3H), 6.61 (t, *J* = 8.3 Hz, 3H), 4.93–4.80 (m, 1H), 4.75 (d, *J* = 1.9 Hz, 1H), 3.27 (dd, *J* = 12.2, 7.1 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ = 146.5, 139.9 (d, *J*_{C-P} = 7.7 Hz), 135.7, 133.4, 133.1, 132.8 (d, *J*_{C-P} = 9.8 Hz), 132.5 (d, *J*_{C-P} = 2.6 Hz), 131.2, 129.7, 129.1, 129.0, 128.8 (d, *J*_{C-P} = 8.6 Hz), 128.7, 128.5, 128.3, 127.8, 126.8, 117.3, 113.7, 62.7, 59.4; HRMS (ESI-TOF) calcd for C₃₂H₂₈ClN₂NaOP [M + Na]⁺ m/z = 545.1520, found 545.1519.

N-(2-(*N*-(Phenyl)-2-(3-bromophenyl)-1-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3q): White solid (80.0 mg, 70%); mp 190–192 °C; $R_f = 0.60$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃) δ = 7.85 (dd, *J* = 12.2, 7.0 Hz, 2H), 7.77 (dd, *J* = 12.3, 7.3 Hz, 2H), 7.57–7.51 (m, 1H), 7.50–7.42 (m, 3H), 7.37–7.27 (m, 6H), 7.07 (t, *J* = 7.9 Hz, 2H), 7.03–6.91 (m, 4H), 6.84 (d, *J* = 7.6 Hz, 1H), 6.64–6.56 (m, 3H), 4.84 (td, *J* = 12.3, 2.6 Hz, 1H), 4.70 (d, *J* = 1.2 Hz, 1H), 3.26 (dd, *J* = 12.2, 7.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ = 146.6, 140.0, 139.7 (d, *J*_{C-P} = 7.3 Hz), 133.1, 132.9 (d, *J*_{C-P} = 9.8 Hz), 132.5 (d, *J*_{C-P} = 2.5 Hz), 132.4 (d, *J*_{C-P} = 2.7 Hz), 131.9, 131.5 (d, *J*_{C-P} = 8.3 Hz), 131.5, 131.2, 130.8, 129.9, 129.7, 129.2, 129.0, 128.9 (d, *J*_{C-P} = 8.3 Hz), 128.7, 128.5, 127.9, 126.8, 122.3, 117.3, 113.6, 63.0, 59.6; HRMS (ESI-TOF) calcd for C₃₂H₂₉BrN₂OP [M + H]⁺ m/z = 567.1195, found 567.1199.

N-(2-(*N*-(Phenyl)-2-(4-*tert*-butylphenyl)-1-phenylethyl)-*P*,*P*diphenylphosphinic Amide (3r): White solid (68.8 mg, 63%); mp 190–191 °C; $R_f = 0.65$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃) δ = 7.95–7.84 (m, 2H), 7.81–7.71 (m, 2H), 7.58–7.39 (m, 4H), 7.34–7.27 (m, 5H), 7.11 (d, *J* = 8.3 Hz, 2H), 7.05 (t, *J* = 7.9 Hz, 2H), 6.97–6.90 (m, 2H), 6.79 (d, *J* = 8.0 Hz 2H), 6.68–6.53 (m, 4H), 4.93–4.68 (m, 2H), 3.43 (dd, *J* = 11.9, 6.8 Hz, 1H), 1.22 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ = 150.3, 147.0, 140.4 (d, *J*_{C-P} = 9.8 Hz), 134.0, 133.5, 132.8 (d, *J*_{C-P} = 9.7 Hz), 132.3 (d, *J*_{C-P} = 2.7 Hz), 132.2 (d, *J*_{C-P} = 7.3 Hz), 131.8 (d, *J*_{C-P} = 9.6 Hz), 131.6, 130.2, 129.1, 128.9, 128.7 (d, *J*_{C-P} = 6.5 Hz), 128.6, 128.1 (d, *J*_{C-P} = 33.7 Hz), 127.5, 127.1, 125.1, 116.7, 113.5, 110.2, 62.7, 59.8, 34.5, 31.4; HRMS (ESI-TOF) calcd for C₃₆H₃₈N₂OP [M + H]⁺ m/z = 545.2716, found 545.2721.

N-(2-(*N*-(Phenyl)-2-(3-methoxyphenyl)-1-phenylethyl)-*P*,*P*diphenylphosphinic Amide (3s): White solid (79.6 mg, 77%); mp 175–177 °C; $R_f = 0.65$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃ major isomer) $\delta = 7.93-7.84$ (m, 2H), 7.82–7.73 (m, 2H), 7.53 (t, *J* = 8.0 Hz, 1H), 7.49–7.39 (m, 3H), 7.35–7.28 (m, 5H), 7.09–6.97 (m, 5H), 6.77 (d, *J* = 7.6 Hz, 1H), 6.69 (dd, *J* = 8.2, 2.0 Hz, 1H), 6.63–6.58 (m, 3H), 6.53 (d, *J* = 7.6 Hz, 1H), 6.29 (s, 1H), 4.85 (td, *J* = 11.9, 2.6 Hz, 1H), 4.73 (dd, *J* = 7.6, 2.7 Hz, 1H), 3.49 (s, 3H), 3.40 (dd, *J* = 12.2, 6.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃ major isomer) δ = 159.2, 147.0, 140.4 (d, *J*_{C-P} = 7.6 Hz), 138.9, 133.3, 132.8 (d, *J*_{C-P} = 9.8 Hz), 132.4 (d, *J*_{C-P} = 2.7 Hz), 132.3 (d, *J*_{C-P} = 8.2 Hz), 132.0, 131.6 (d, *J*_{C-P} = 9.7 Hz), 131.4, 130.1, 129.2, 129.1, 128.9, 128.8 (d, *J*_{C-P} = 5.8 Hz), 128.6, 128.3, 127.5, 127.0, 120.5, 116.9, 114.0, 113.5, 113.1, 63.3, 59.5, 55.0; HRMS (ESI-TOF) calcd for C₃₃H₃₂N₂O₂P [M + H]⁺ *m*/*z* = 519.2196, found 519.2196.

N-(2-(*N*-(Phenyl)-2-(3-methylphenyl)-1-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3t): White solid (78.8 mg, 79%); mp 120–122 °C; *R*_f = 0.65 (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, C_6D_6) δ = 8.04–7.92 (m, 4H), 7.85 (d, *J* = 7.3 Hz, 1H), 7.13 (t, *J* = 7.8 Hz, 2H), 7.07–6.93 (m, 9H), 6.93–6.86 (m, 2H), 6.85–6.75 (m, 3H), 6.71 (d, *J* = 7.0 Hz, 1H), 6.68–6.59 (m, 3H), 4.95 (td, *J* = 12.2, 2.2 Hz, 1H), 4.75 (dd, *J* = 6.9, 2.0 Hz, 1H), 3.43 (dd, *J* = 12.4, 6.4 Hz, 1H), 1.85 (s, 3H); ¹³C NMR (100 MHz, C_6D_6) δ = 148.0, 141.2 (d, *J*_{C-P} = 8.2 Hz), 137.7 (d, *J*_{C-P} = 5.1 Hz), 134.4, 133.2 (d, *J*_{C-P} = 9.6 Hz), 133.1, 132.5, 132.1 (d, *J*_{C-P} = 2.7 Hz), 131.7 (d, *J*_{C-P} = 9.5 Hz), 131.1, 129.6, 129.5, 129.0, 128.9 (d, *J*_{C-P} = 2.6 Hz), 128.7, 128.2, 127.4, 127.2, 125.9, 117.1, 113.8, 63.6, 59.9, 21.2; HRMS (ESI-TOF) calcd for $C_{33}H_{32}N_2OP$ [M + H]⁺ *m*/*z* = 503.2247, found 503.2242.

N-(2-(*N*-(Phenyl)-2-(2-methylphenyl)-1-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3u): White solid (69.8 mg, 70%); mp 145–146 °C; $R_f = 0.62$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃) δ = 7.91 (dd, *J* = 11.9, 7.5 Hz, 2H), 7.75 (dd, *J* = 12.1, 7.6 Hz, 2H), 7.56–7.50 (m, 1H), 7.50–7.41 (m, 4H), 7.36–7.27 (m, 5H), 7.23 (d, *J* = 6.9 Hz, 1H), 7.10–7.06 (m, 4H), 6.97 (d, *J* = 7.3 Hz, 1H), 6.80 (d, *J* = 7.2 Hz, 2H), 6.59 (t, *J* = 7.3 Hz, 3H), 5.00 (s, 1H), 4.78 (t, *J* = 11.4 Hz, 1H), 3.79 (dd, *J* = 12.0, 7.3 Hz, 1H), 1.60 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 146.5, 139.9 (d, *J*_{C-P} = 7.5 Hz), 137.6, 135.5, 133.2, 132.8 (d, *J*_{C-P} = 9.8 Hz), 132.3 (d, *J*_{C-P} = 2.7 Hz), 130.2, 129.1, 128.9, 128.7 (d, *J*_{C-P} = 8.5 Hz), 128.6, 128.4, 127.7, 127.4 (d, *J*_{C-P} = 10.5 Hz), 127.0, 125.9, 117.4, 113.7, 59.3, 58.3, 18.8; HRMS (ESI-TOF) calcd for C₃₃H₃₂N₂OP [M + H]⁺ m/z = 503.2247, found 503.2244.

N-(2-(*N*-(Phenyl)-2-(3,5-dimethylphenyl)-1-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3v): White solid (93.3 mg, 90%); mp 199–200 °C; $R_f = 0.50$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, C_6D_6) $\delta = 7.97$ (dd, J = 11.9, 7.5 Hz, 4H), 7.89 (d, J = 7.2 Hz, 1H), 7.13 (d, J = 7.4 Hz, 2H), 7.09–6.94 (m, 9H), 6.93–6.86 (m, 2H), 6.69–6.59 (m, 5H), 6.55 (s, 1H), 4.95 (td, J = 12.3, 2.1 Hz, 1H), 4.73 (dd, J = 7.2, 2.2 Hz, 1H), 3.43 (dd, J = 12.4, 6.3 Hz, 1H), 1.82 (s, 6H); ¹³C NMR (100 MHz, C_6D_6) $\delta = 148.1$, 141.4 (d, $J_{C-P} = 8.4$ Hz), 137.6, 137.5, 134.6, 133.3 (d, $J_{C-P} = 9.7$ Hz), 132.5, 132.13 (d, $J_{C-P} = 2.6$ Hz), 132.08 (d, $J_{C-P} = 2.7$ Hz), 131.7 (d, $J_{C-P} = 9.8$ Hz), 131.2, 129.62, 129.58, 128.9 (d, $J_{C-P} = 6.1$ Hz), 128.8 (d, $J_{C-P} = 6.4$ Hz), 128.1, 127.3, 126.7, 117.0, 113.7, 63.7, 59.9, 21.1; HRMS (ESI-TOF) calcd for $C_{34}H_{34}N_2$ OP [M + H]⁺ m/z = 517.2403, found 517.2406.

N-(2-(*N*-(Phenyl)-2-(3,4-dimethylphenyl)-1-phenylethyl)-*P*,*P*-diphenylphosphinic Amide (3w): White solid (93.0 mg, 90%); mp 123–124 °C; $R_f = 0.50$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400

MHz, C_6D_6 , major isomer) $\delta = 8.05-7.83$ (m, 5H), 7.15–7.09 (m, 2H), 7.09–7.05 (m, 3H), 7.05–6.99 (m, 5H), 6.98–6.94 (m, 1H), 6.94–6.87 (m, 2H), 6.77 (d, J = 6.1 Hz, 2H), 6.71–6.62 (m, 4H), 4.95 (td, J = 12.2, 2.1 Hz, 1H), 4.76 (dd, J = 7.4, 2.2 Hz, 1H), 3.47 (dd, J = 12.3, 6.1 Hz, 1H), 1.81 (s, 3H), 1.75 (s, 3H); ¹³C NMR (100 MHz, C_6D_6 , major isomer) $\delta = 148.1$, 141.4 (d, $J_{C-P} = 8.4$ Hz), 139.4, 136.2, 135.8, 135.0, 134.4, 133.2 (d, $J_{C-P} = 9.6$ Hz), 132.5, 132.1, 131.8 (d, $J_{C-P} = 9.6$ Hz), 131.2, 130.1, 129.7, 129.5, 129.0, 128.8, 128.7, 127.3, 126.4, 117.0, 113.8, 63.4, 59.9, 19.5, 19.3; HRMS (ESI-TOF) calcd for $C_{34}H_{33}N_2NaOP$ [M + Na]⁺ m/z = 539.2223, found 539.2224.

N-(2-(N-(4-Methoxyphenyl)-1-(4-methylphenyl)-2-phenylethyl)-P,P-diphenylphosphinic Amide (3x). According to the general procedure for 3, 11 (638 mg, 1.83 mmol) and 2c (879 mg, 2.75 mmol) were used to afford the product 3x (830 mg, 85%) as a white solid: mp 113–114 °C; $R_f = 0.40$ (hexanes/ethyl acetate = 1/1); ¹H NMR (400 MHz, CDCl₃) δ = 7.88 (dd, J = 11.9, 7.9 Hz, 2H), 7.77 (dd, J = 12.0, 7.9 Hz, 2H), 7.54-7.48 (m, 1H), 7.47-7.39 (m, 3H), 7.35-7.27 (m, 2H), 7.18-7.06 (m, 5H), 6.89 (d, J = 6.3 Hz, 2H), 6.82 (d, J = 7.7 Hz, 2H), 6.66 (d, J = 8.7 Hz, 2H), 6.57 (d, J = 8.6 Hz, 2H),6.23 (d, J = 8.3 Hz, 1H), 4.84-4.67 (m, 2H), 3.67 (s, 3H), 3.38 (dd, J = 11.8, 6.7 Hz, 1H), 2.38 (s, 3H); 13 C NMR (100 MHz, CDCl₃) δ = 151.7, 141.2, 137.6, 137.2 (d, $J_{C-P} = 7.8$ Hz), 137.1, 133.5, 132.8 (d, $J_{C-P} = 9.8$ Hz), 132.2 (d, $J_{C-P} = 2.6$ Hz), 132.1 (d, $J_{C-P} = 2.6$ Hz), 131.7 (d, $J_{C-P} = 9.5 \text{ Hz}$), 130.3, 129.0, 128.9, 128.7 (d, $J_{C-P} = 4.7 \text{ Hz}$), 128.6, 128.4, 128.1, 127.4, 126.8, 114.80, 114.76, 63.9, 59.6, 55.8, 21.3; HRMS (ESI-TOF) calcd for $C_{34}H_{34}N_2O_2P [M + H]^+ m/z = 533.2352$, found 533.2358

1-Diphenylphosphinyl-3-(4-methoxyphenyl)-4-phenyl-5-(4methylphenyl)imidazolidin-2-one (6). 3x (266 mg, 0.5 mmol) was dissolved in 8.0 mL of THF and added to a flame-dried Schlenk flask under argon. The solution was cooled to -78 °C, n-BuLi (1.5 mmol, 3.0 equiv) was added dropwise to the solution via syringe, and the reaction mixture was stirred for 0.5 h at -78 °C. Then CbzCl (1.5 mmol, 3.0 equiv) was added dropwise, and the reaction mixture was warmed to room temperature and stirred for another 2 h. The reaction was quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate $(3 \times 20 \text{ mL})$. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by flash column chromatography using (hexanes/ethyl acetate = 1/1) as eluent afforded the product 6 (237 mg, 85%) as a white solid: mp 238-240 °C; $R_f = 0.35$ (hexanes/ethyl acetate = 1/2); ¹H NMR (400 MHz, $CDCl_3$) δ = 7.92 (dd, J = 12.8, 7.6 Hz, 2H), 7.78 (dd, J = 13.1, 7.6 Hz, 2H), 7.57-7.46 (m, 2H), 7.46-7.35 (m, 4H), 7.12 (d, J = 8.8 Hz, 2H), 7.04-6.87 (m, 3H), 6.90-6.58 (m, 8H), 5.80 (d, J = 8.2 Hz, 1H), 5.47 (d, J = 6.6 Hz, 1H), 3.67 (s, 3H), 2.13 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 158.2 (d, $J_{\rm C-P}$ = 5.9 Hz), 156.7, 137.2, 134.1, 133.4, 132.7 (d, $J_{C-P} = 10.7 \text{ Hz}$), 132.34 (d, $J_{C-P} = 3.1 \text{ Hz}$), 132.30 (d, $J_{\rm C-P} = 3.0$ Hz), 132.2, 131.8 (d, $J_{\rm C-P} = 10.9$ Hz), 131.2, 130.9, 130.6, 129.9, 128.5, 128.4, 128.2 (d, $J_{C-P} = 5.7 \text{ Hz}$), 128.1 (d, $J_{C-P} = 3.4 \text{ Hz}$), 127.9, 127.6, 124.1, 113.9, 65.9, 62.0, 55.4, 21.1; HRMS (ESI-TOF) calcd for $C_{35}H_{32}N_2O_3P [M + H]^+ m/z = 559.2145$, found 559.2144.

3-(4-Methoxyphenyl)-4-phenyl-5-(4-methylphenyl)-imidazolidin-2-one (\$1). A flame-dried flask was charged with 6 (157 mg, 0.28 mmol) and NaOMe (2.8 mmol, 151 mg, 10 equiv); after addition of MeOH (10 mL), the reaction mixture was maintained at room temperature for 1 h. The reaction mixture was then diluted with H₂O and extracted three times with EtOAc. The organic layers were combined, washed with brine, dried over Na2SO4, and concentrated. Purification by flash column chromatography on silica gel using hexanes/ethyl acetate = 2/1 as eluent affords the product S1 (90.2 mg, 89%) as a white solid: mp 219–220 °C; $R_f = 0.45$ (hexanes/ethyl acetate = 1:1); ¹H NMR (400 MHz, CDCl₃) δ = 7.33 (d, J = 8.9 Hz, 2H), 7.02 (d, J = 4.9 Hz, 3H), 6.92–6.82 (m, 6H), 6.75 (d, J = 8.9 Hz, 2H), 5.43 (d, J = 8.4 Hz, 1H), 5.22 (d, J = 8.5 Hz, 1H), 5.09 (s, 1H), 3.70 (s, 3H), 2.20 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 160.5, 155.9, 137.6, 135.5, 133.7, 131.9, 128.8, 128.1, 127.74, 127.68, 127.2, 122.4, 114.1, 66.5, 59.6, 55.5, 21.0; HRMS (ESI-TOF) calcd for $C_{23}H_{23}N_2O_2 [M + H]^+ m/z = 359.1754$, found 359.1749.

The Journal of Organic Chemistry

4-Phenyl-5-(4-methylphenyl)imidazolidin-2-one (S2). To a solution of S1 (69.0 mg, 0.20 mmol) in CH₃CN and water (12.5 mL, v/v 5:1) was added the solution of cerium ammonium nitrate (CAN, 270 mg, 0.50 mmol, 2.5 equiv) in water (2.5 mL) over a time of 0.5 h via a syringe pump at 0 °C. After the mixture was stirred for another 0.5 h, saturated aqueous NaHCO3 was added. Then the aqueous layer was extracted with ethyl acetate and dried over Na2SO4. The crude product was purified by flash column chromatography using (dichloromethane/ethyl acetate = 1/1) as eluent to afford the compound S2 (34.2 mg, 69%) as a white solid: mp 220-221 °C; R_f =0.25 (dichloromethane/ethyl acetate = 1:1); ¹H NMR (400 MHz, $CDCl_3$) $\delta = 7.14-7.05$ (m, 3H), 6.99-6.92 (m, 2H), 6.88 (d, J = 7.9Hz, 2H), 6.82 (d, J = 8.0 Hz, 2H), 5.14 (s, 4H), 2.19 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 164.2, 137.6, 137.0, 133.8, 128.8, 128.1, 127.9, 127.2, 127.1, 62.0, 61.9, 21.1; HRMS (ESI-TOF) calcd for $C_{16}H_{17}N_2O [M + H]^+ m/z = 253.1335$, found 253.1331.

anti-I,2-Diamino-L-phenyl-2-(4-methylphenyl)ethane (7).⁵⁶ S2 (45.0 mg, 0.18 mmol) in the solution of 47% aqueous HBr (2.0 mL) and HOAc (1.0 mL) was refluxed for 24 h, then the solvent was concentrated in vacuo. Aqueous NaOH (2.0 mL, 1.0 N) was added to the reaction mixture. After extraction with EtOAc, the combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by flash column chromatography (dichloromethane/methanol = 20/1) as eluent to give 37.3 mg (88%) of 7 as a white solid: mp 90–91 °C; R_f = 0.22 (dichloromethane/methanol = 20/1); ¹H NMR (400 MHz, CDCl₃) δ = 7.37–7.24 (m, 4H), 7.24–7.16 (m, 3H), 7.08 (d, *J* = 7.6 Hz, 2H), 3.91 (s, 2H), 2.27 (s, 3H), 1.32 (s, 4H); ¹³C NMR (100 MHz, CDCl₃) δ = 143.2, 140.0, 137.4, 129.3, 128.6, 127.74, 127.69, 127.6, 62.9, 62.7, 21.2; HRMS (ESI-TOF) calcd for C₁₅H₁₉N₂ [M + H]⁺ m/z = 227.1543, found 227.1540.

ASSOCIATED CONTENT

S Supporting Information

¹H and ¹³C NMR spectra of all new compounds, X-ray crystal structure of compound **3a**. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Authors

*E-mail: xuyj@ms.xjb.ac.cn.

*E-mail: clu@ms.xjb.ac.cn.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by the National Natural Science Foundation of China (U1403301, 21372255, and 21172251), the YCSTTC Project of Xinjiang Uygur Autonomous Region (2013711017), and the Recruitment Program of Global Experts (Xinjiang Program).

REFERENCES

(1) Lucet, D.; Le Gall, T.; Mioskowski, C. Angew. Chem., Int. Ed. 1998, 37, 2580.

(2) Savoia, D. Top. Organomet. Chem. 2005, 15, 1.

- (3) Kotti, S. R. S. S.; Timmons, C.; Li, G. Chem. Biol. Drug Des. 2006, 67, 101.
- (4) Kim, H.; So, S. M.; Chin, J.; Kim, B. M. Aldrichimica Acta 2008, 41, 77.
- (5) Faugeroux, V.; Genisson, Y. Curr. Org. Chem. 2008, 12, 751.
- (6) Cardona, F.; Goti, A. Nat. Chem. 2009, 1, 269.
- (7) De Jong, S.; Nosal, D. G.; Wardrop, D. J. *Tetrahedron* **2012**, *68*, 4067.
- (8) Noble, A.; Anderson, J. C. Chem. Rev. 2013, 113, 2887.
- (9) So, S. M.; Mui, L.; Kim, H.; Chin, J. Acc. Chem. Res. 2012, 45, 1345 and references cited therein.

(10) Turnpenny, B. W.; Chemler, S. R. Chem. Sci. 2014, 5, 1786 and references cited therein.

(11) Zhu, Y.; Cornwall, R. G.; Du, H.; Zhao, B.; Shi, Y. Acc. Chem. Res. 2014, 47, 3665 and references cited therein.

(12) Muñiz, K.; Martínez, C. J. Org. Chem. 2013, 78, 2168 and references cited therein.

(13) Matsumoto, M.; Harada, M.; Yamashita, Y.; Kobayashi, S. *Chem. Commun.* **2014**, *50*, 13041 and references cited therein.

(14) For enantioselective construction of *anti*-1,2-diaryl-1,2-diamines via aza-Henry reaction (also called nitro-Mannich reaction) followed by nitro-reduction, see: Davis, T. A.; Johnston, J. N. *Chem. Sci.* **2011**, *2*, 1076 and ref 15.

(15) Vara, B. A.; Mayasundari, A.; Tellis, J. C.; Danneman, M. W.; Arredondo, V.; Davis, T. A.; Min, J.; Finch, K.; Guy, R. K.; Johnston, J. N. J. Org. Chem. **2014**, *79*, 6913.

(16) For recent review of nitro-Mannich reaction, see: Noble, A.; Anderson, J. C. *Chem. Rev.* **2013**, *113*, 2887.

(17) For recent example of asymmetric organocatalytic nitro-Mannich reaction, see: Wang, B.; Liu, Y.; Sun, C.; Wei, Z.; Cao, J.; Liang, D.; Lin, Y.; Duan, H. *Org. Lett.* **2014**, *16*, 6432.

(18) For addition of α -amino carbanions to imines affording aryl *syn*-1,2-diamines, see: Kise, N.; Kashiwagi, K.; Watanabe, M.; Yoshida, J. J. *Org. Chem.* **1996**, *61*, 428 and refs 19–24. For solvent- and substratedependent *anti*-selective formation of 1,2-diamines via addition of α amino carbanions to imines, see ref 13.

(19) Park, Y. S.; Boys, M. L.; Beak, P. J. Am. Chem. Soc. 1996, 118, 3757.

(20) Chen, Y.-J.; Seki, K.; Yamashita, Y.; Kobayashi, S. J. Am. Chem. Soc. 2010, 132, 3244.

(21) Gaul, C.; Schärer, K.; Seebach, D. J. Org. Chem. 2001, 66, 3059.
(22) Katritzky, A. R.; Luo, Z. S.; Fang, Y.; Steel, P. J. J. Org. Chem. 2001, 66, 2858.

(23) Shibahara, F.; Kobayashi, S.; Maruyama, T.; Murai, T. Chem.— Eur. J. 2013, 19, 304.

(24) Liu, X.; Gao, A.; Ding, L.; Xu, J.; Zhao, B. Org. Lett. 2014, 16, 2118.

(25) For selected reviews of Brook rearrangement and its applications in synthesis, see: Brook, A. G. Acc. Chem. Res. 1974, 7, 77 and refs 26–28.

(26) Bulman, P. C.; Klair, S. S.; Rosenthal, S. Chem. Soc. Rev. 1990, 19, 147.

(27) Moser, W. H. Tetrahedron 2001, 57, 2065.

(28) Boyce, G. R.; Greszler, S. N.; Johnson, J. S.; Linghu, X.; Malinowski, J. T.; Nicewicz, D. A.; Satterfield, A. D.; Schmitt, D. C.; Steward, K. M. J. Org. Chem. **2012**, *77*, 4503.

(29) Brook, A. G.; Duff, J. M. J. Am. Chem. Soc. 1974, 96, 4692.

(30) Duff, J. M.; Brook, A. G. Can. J. Chem. 1977, 55, 2589.

- (31) For examples of [1,2]-aza-Brook rearrangement, see: Suginome, M.; Fukuda, T.; Ito, Y. J. Organomet. Chem. 2002, 643–644, 508 and refs 32 and 33.
- (32) Honda, T.; Mori, M. J. Org. Chem. 1996, 61, 1196.

(33) Shimizu, M.; Takao, Y.; Katsurayama, H.; Mizota, I. Asian J. Org. Chem. 2013, 2, 130.

(34) For examples of retro-[1,2]-aza-Brook rearrangement, see: Sieburth, S. M.; O'Hare, H. K.; Xu, J.; Chen, Y.; Liu, G. *Org. Lett.* **2003**, 5, 1859 and ref 35.

(35) Liu, G.; Sieburth, S. M. Org. Lett. 2003, 5, 4677.

(36) For examples of [1,3]-aza-Brook rearrangement, see: Fuji, K.; Ueda, M.; Sumi, K.; Fujita, E. J. Org. Chem. **1985**, 50, 662 and refs 37 and 38.

(37) Page, P. C. B.; van Niel, M. B.; Westwood, D. J. Chem. Soc., Perkin Trans. 1 1988, 269.

(38) Yagi, K.; Tsuritani, T.; Takami, K.; Shinokubo, H.; Oshima, K. J. Am. Chem. Soc. **2004**, 126, 8618.

(39) For fluoride-triggered generation of α -amino carbanion from α silylamine, see: Mita, T.; Chen, J.; Sugawara, M.; Sato, Y. *Org. Lett.* **2012**, *14*, 6202 and ref 40.

(40) Mita, T.; Sugawara, M.; Saito, K.; Sato, Y. Org. Lett. 2014, 16, 3028.

The Journal of Organic Chemistry

(41) See the Supporting Information for the X-ray crystal structure of diamine **3a**.

(42) When chiral *N-tert*-butylsulfinyl imine derived from benzaldehyde was used, the coupling product was obtained in 89% yield with low diastereoselectivity (3:3:1:0 dr). The reason is unclear why the reaction behaviors of the *N*-tosyl or *N*-Boc imines are different from that of the *N*-diphenylphosphinyl or *N-tert*-butylsulfinyl derivatives.

(43) Comparable yields and *anti/syn* ratios were achieved when the *N*-aryl-substituted variants of 1 were varied. For example, *N*-(4-methoxyphenyl) and *N*-(4-bromophenyl) α -phenyl α -silylamines were used in the coupling reactions with **2a** to give the corresponding diamines, respectively, in 78% yield with 11:1 dr and in 79% yield with 12:1 dr. A lower yield of 56% and a lower *anti/syn* ratio of 5:1 were observed for the reaction of *N*-phenyl α -silylamine bearing Ph₂MeSi- instead of PhMe₂Si- at the α -position.

(44) Bloch, R. Chem. Rev. 1998, 98, 1407.

(45) For synthesis of α -silylamines, see: Ballweg, D. M.; Miller, R. C.; Gray, D. L.; Scheidt, K. A. *Org. Lett.* **2005**, *7*, 1403 and references 46–50.

(46) Nielsen, L.; Lindsay, K. B.; Faber, J.; Nielsen, N. C.; Skrydstrup, T. J. Org. Chem. 2007, 72, 10035.

(47) Vyas, D. J.; Frohlich, R.; Oestreich, M. Org. Lett. 2011, 13, 2094.

(48) Han, X.-J.; Yao, M.; Lu, C.-D. Org. Lett. 2012, 14, 2906.

(49) Hensel, A.; Nagura, K.; Delvos, L. B.; Oestreich, M. Angew. Chem., Int. Ed. 2014, 53, 4964.

(50) Niljianskul, N.; Zhu, S.; Buchwald, S. L. Angew. Chem., Int. Ed. 2015, 54, 1638.

(51) Notably, transmetalation of the nucleophilic silyl reagent from PhMe₂SiLi to PhMe₂Si-MgiPr·LiCl is required in the reactions with *N*-aryl imines in order to improve the yield of the desired α -silylamines. For selected example of synthetic applications of PhMe₂Si-MgMe, see: Okuda, Y.; Morizawa, Y.; Oshima, K.; Nozaki, H. *Tetrahedron Lett.* **1984**, 25, 2483.

(52) The coupling reactions occurred when the heteroaryl α -silylamines derived from 2-furaldehyde and 2-thenaldehyde were used. However, attempts to isolate pure products by column chromatography failed.

(53) Our studies of direct removal of DPP and PMP groups from 3x gave unsatisfactory results.

(54) Jennings, W. B.; Lovely, C. J. Tetrahedron 1991, 47, 5561.

(55) Fleming, I.; Newton, T. W.; Roessler, F. J. Chem. Soc., Perkin Trans. 1 1981, 2527.

(56) Pansare, S. V.; Malusare, M. G. Tetrahedron Lett. 1996, 37, 2859.